We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




Beckman Coulter and Ortho Clinical Partner to Deliver Infectious Disease Testing Menu

By LabMedica International staff writers
Posted on 04 Jul 2016
Beckman Coulter, Inc., (Brea, California, USA) and Ortho Clinical Diagnostics (Raritan, New Jersey, USA) have entered a strategic relationship for marketing Ortho's VITROS 3600 Immunodiagnostic System and infectious disease menu in the United States.

Ortho's VITROS 3600 System combines three high-quality proprietary technologies into a single self-monitoring system and offers a broad menu of infectious disease tests that are used by a number of leading reference laboratories in the United States. More...
Beckman Coulter will place the VITROS 3600 System running HIV and hepatitis assays in labs that currently run its Power Processor Sample Handling Systems, and other very high-volume laboratories. This will allow very high-volume laboratories to access state-of-the-art infectious disease testing on the VITROS 3600 System and help them improve operational efficiency as well as patient care.

Beckman Coulter and Ortho will also collaborate to obtain clearance/approval from the U.S. Food and Drug Administration to connect the VITROS 3600 System to the Power Processor to run infectious disease tests.

"We look forward to working with the impressive team at Ortho to bring Ortho's high-quality infectious disease testing to our customers," said John Nosenzo, senior vice president, Customer Operations, Developed Markets at Beckman Coulter. "This relationship provides both immediate opportunity and long-term value as we continue to enhance efficiency, advance patient care and broaden our customer offerings. Through this relationship, we will be able to apply innovative technologies to deliver enhanced solutions to the highest-volume labs in the U.S."

"Ortho has long been a pioneer in infectious disease testing. Our relationship with Beckman will help us deliver that expertise to their large installed base of automated labs," said Alex Socarrás, executive vice president, Global Commercial Operations at Ortho. "We are committed to forming key strategic collaborations such as this one, which enable us to stay focused on our core business while being nimble enough to meet the varied and changing needs of our valued customers."

Related Links:
Beckman Coulter
Ortho Clinical Diagnostics

Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.